Lung Cancer Prevention Screening Programme in Italy
Early Diagnosis of Lung Cancer of the Italian Pulmonary Screening Network (RISP): Comparative Analysis for the Use of Low Dose Computed Tomography and Promotion of Primary Prevention Interventions in Subjects at High Risk for Lung Cancer
Ugo Pastorino
7,324 participants
Sep 17, 2022
INTERVENTIONAL
Conditions
Summary
This prospective randomized multicentered clinical study aims at implementing early diagnosis of lung cancer in high-risk heavy smokers in the Italian population. The main goal of the study is to develop a nationwide lung cancer prevention screening with high quality standard, similar to that of other screening programs i.e. breast, colon and cervix ongoing in Italy. The Italian Pulmonary Screening Network (RISP) includes 18 centers, which will promote primary prevention by offering a smoking cessation program (i.e. counselling and anti-smoking cytisine-based therapy) and secondary prevention by screening volunteers with chest Low Dose Computed Tomography (LDCT). The primary objective of the study is to demonstrate the non-inferiority of a risk-based screening strategy (less intensive, every 2 years) compared to the standard annual screening, in terms of stage I/II lung cancer incidence. Furthermore, the study aims to provide evidence whether blood biomarkers screening intervals can improve the efficiency of lung cancer screening by requiring less CT examinations while retaining the ability to diagnose lung cancer at curative state.
Eligibility
Inclusion Criteria4
- Active smoker (≥ 30 packs/year)
- Former heavy smoker for ≤ 15 years (≥ 30 packs/year)
- Absence of tumors for at least 5 years
- Signature of informed consent for studio enrollment and processing of personal data
Exclusion Criteria3
- Severe chronic disease (e.g. severe respiratory and/or renal and/or hepatic and/or cardiac failure)
- Severe psychiatric problems
- Abuse of alcohol or other substances (including previous)
Interventions
standard treatment for early lung cancer detection with LDCT at one or two years interval
blood analysis for microRNA and other biomarkers detection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05766046